Imaging of the myocardium using 18 F-FDG-PET/MRI

Anti-signal Recognition Particle Antibody-positive Necrotizing Myopathy with Secondary Cardiomyopathy: The First Myocardial Biopsy- and Multimodal Imaging-proven Case

A 69-year-old Japanese woman was admitted to our hospital with progressive muscle weakness and dysphagia. She was taking pitavastatin for dyslipidemia. Her serum creatine kinase was 6,300 U/L. Pitavastatin was stopped, but her symptoms deteriorated, and cardiac congestion appeared. A muscle biopsy showed necrotizing myopathy (NM), and anti-signal recognition particle (SRP) antibody was positive. ¹⁸F-fluorodeoxyglucose-positron emission tomography showed an abnormal uptake, and magnetic resonance imaging showed abnormal gadolinium enhancement in the left ventricular wall. An endomyocardial biopsy revealed inflammatory cardiomyopathy. Steroid, tacrolimus, and intravenous immunoglobulins were effective against the symptoms. This is the first case of biopsy-proven secondary cardiomyopathy due to anti-SRP-positive NM.

PET/MRI of the thorax, abdomen and retroperitoneum: Benefits of the breathing-synchronized scanning

Hybrid imaging using various radiopharmaceuticals is currently essential not only in detection and therapy response monitoring of tumors, but also in assessment of inflammatory or systemic diseases. Combination of positron emission tomography (PET) and magnetic resonance imaging (MRI) is still relatively new method with great prospects of comprehensive assessment using anatomical and multiple functional information. However, benefits of PET/MRI in thorax, abdomen and retroperitoneum are not completely defined. Breathing movements affect imaging of thoracic, abdominal and retroperitoneal organs and pathological structures using PET and MRI. Fast MRI sequences are performed using breath-hold technique; however, acquisition of longer sequences and PET scanning need to be breathing-synchronized. Review article summarizes concrete PET/MRI protocols and importance of concrete MRI sequences and radiopharmaceuticals in different pathological lesions with focus on benefit of breathing-synchronized techniques.

Clinical Applications of Small-molecule PET Radiotracers: Current Progress and Future Outlook

Radiotracers, or radiopharmaceuticals, are bioactive molecules tagged with a radionuclide used for diagnostic imaging or radiotherapy and, when a positron-emitting radionuclide is chosen, the radiotracers are used for PET imaging. The development of novel PET radiotracers in many ways parallels the development of new pharmaceuticals, and small molecules dominate research and development pipelines in both disciplines. The 4 decades since the introduction of [¹⁸F]FDG have seen the development of many small molecule PET radiotracers. Ten have been approved by the US Food and Drug Administration as of 2016, whereas hundreds more are being evaluated clinically. These radiotracers are being used in personalized medicine and to support drug discovery programs where they are greatly improving our understanding of and ability to treat diseases across many areas of medicine including neuroscience, cardiovascular medicine, and oncology.